Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Common Equity (2025)

Historic Common Equity for Dr Reddys Laboratories (RDY) over the last 15 years, with Q3 2025 value amounting to $4.2 billion.

  • Dr Reddys Laboratories' Common Equity rose 1238.97% to $4.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 billion, marking a year-over-year increase of 1238.97%. This contributed to the annual value of $3.9 billion for FY2025, which is 1646.26% up from last year.
  • Per Dr Reddys Laboratories' latest filing, its Common Equity stood at $4.2 billion for Q3 2025, which was up 1238.97% from $3.9 billion recorded in Q1 2025.
  • In the past 5 years, Dr Reddys Laboratories' Common Equity registered a high of $4.2 billion during Q3 2025, and its lowest value of $2.4 billion during Q1 2021.
  • Moreover, its 5-year median value for Common Equity was $2.9 billion (2023), whereas its average is $3.1 billion.
  • Per our database at Business Quant, Dr Reddys Laboratories' Common Equity skyrocketed by 420.19% in 2022 and then soared by 2061.28% in 2024.
  • Dr Reddys Laboratories' Common Equity (Quarter) stood at $2.5 billion in 2021, then rose by 4.2% to $2.6 billion in 2022, then rose by 18.36% to $3.1 billion in 2023, then rose by 20.61% to $3.7 billion in 2024, then increased by 12.39% to $4.2 billion in 2025.
  • Its last three reported values are $4.2 billion in Q3 2025, $3.9 billion for Q1 2025, and $3.7 billion during Q3 2024.